SRD MRD PoCM in wAMD
Research payments
$592,376
Through program year 2023, $592,376 in research payments was reported against SRD MRD PoCM in wAMD, across 43 payments.
- Paid by (largest first)
- Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim Pharma GmbH & Co.KG
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $286,799 | 19 |
| 2022 | Research | $155,302 | 16 |
| 2021 | Research | $130,902 | 6 |
| 2020 | Research | $19,372 | 2 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Brian Berger Austin, TX Named on 7 payments
- Allen Hu Martinsburg, WV Named on 5 payments
- David Brown Cypress, TX Named on 4 payments
- Peter Chang Worcester, MA Named on 2 payments
- Henry Kwong Scottsdale, AZ Named on 2 payments
- Albert Edwards Eugene, OR Named on 2 payments
- David Almeida Erie, PA Named on 2 payments
- Quan Nguyen Palo Alto, CA Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.